<?xml version="1.0" encoding="utf-8"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Hemisphere Gps Inc.</title><link>https://investorshangout.com/Hemisphere-Gps-Inc-HEM-70168/</link><description><![CDATA[Hemisphere Gps Inc. (HEM)]]></description><language>en-us</language><pubDate>Fri, 16 Oct 2026 20:33:01 GMT</pubDate><copyright>Copyright InvestorsHangout.com</copyright><atom:link href="https://investorshangout.com/Hemisphere-Gps-Inc-HEM-70168/" rel="self" type="application/rss+xml"/><item><title>David Pine: Hemostemix ($HEM) utilizes its technology platform to create autologous cell therapies, with a 52-we</title><link>https://investorshangout.com/post/view?id=6706719</link><guid>https://investorshangout.com/post/view?id=6706719</guid><description><![CDATA[David Pine
]]></description><pubDate>Mon, 15 Jul 2024 15:44:45 GMT</pubDate></item><item><title>Jack Mallick: Hemostemix Inc. ($HEM), a pioneer in regenerative medicine, harnesses the power of blood-derived ste</title><link>https://investorshangout.com/post/view?id=6688006</link><guid>https://investorshangout.com/post/view?id=6688006</guid><description><![CDATA[Jack Mallick
]]></description><pubDate>Thu, 25 Apr 2024 14:28:50 GMT</pubDate></item><item><title>Jack Mallick: Experience the future of healthcare with Hemostemix Inc. ($HEM), a leader in developing advanced tre</title><link>https://investorshangout.com/post/view?id=6687568</link><guid>https://investorshangout.com/post/view?id=6687568</guid><description><![CDATA[Jack Mallick
]]></description><pubDate>Wed, 24 Apr 2024 13:47:48 GMT</pubDate></item><item><title>James Macho: $HEM&#039;s disappointing stock performance raises</title><link>https://investorshangout.com/post/view?id=6638649</link><guid>https://investorshangout.com/post/view?id=6638649</guid><description><![CDATA[James Macho
]]></description><pubDate>Mon, 30 Oct 2023 13:47:44 GMT</pubDate></item><item><title>MatthewDavies: Hemostemix Inc. (TSXV: $HEM) (OTCQB: </title><link>https://investorshangout.com/post/view?id=6489319</link><guid>https://investorshangout.com/post/view?id=6489319</guid><description><![CDATA[MatthewDavies
]]></description><pubDate>Tue, 25 Oct 2022 17:26:39 GMT</pubDate></item><item><title>IR_CONSULTING_HEAD: Hemsotemix just released clinical trial results from heart failure and limb ischemia t</title><link>https://investorshangout.com/post/view?id=6488297</link><guid>https://investorshangout.com/post/view?id=6488297</guid><description><![CDATA[IR_CONSULTING_HEAD
]]></description><pubDate>Fri, 21 Oct 2022 18:27:24 GMT</pubDate></item><item><title>MatthewDavies: (TSX.V: $HEM) Hemostemix has employed Dr. Terry Hébert</title><link>https://investorshangout.com/post/view?id=6488296</link><guid>https://investorshangout.com/post/view?id=6488296</guid><description><![CDATA[MatthewDavies
]]></description><pubDate>Fri, 21 Oct 2022 18:25:56 GMT</pubDate></item><item><title>jennifer_john: Investors must not miss! ACP01 hemostemix lead clinical stage candidate will be the 1st to patien</title><link>https://investorshangout.com/post/view?id=6488294</link><guid>https://investorshangout.com/post/view?id=6488294</guid><description><![CDATA[jennifer_john
]]></description><pubDate>Fri, 21 Oct 2022 18:24:29 GMT</pubDate></item><item><title>MatthewDavies: $HEM has announced the closing of convertible d</title><link>https://investorshangout.com/post/view?id=6408401</link><guid>https://investorshangout.com/post/view?id=6408401</guid><description><![CDATA[MatthewDavies
]]></description><pubDate>Mon, 23 May 2022 15:15:10 GMT</pubDate></item></channel></rss>